Macphee G J, Thompson G G, Scobie G, Agnew E, Park B K, Murray T, McColl K E, Brodie M J
Br J Clin Pharmacol. 1984 Sep;18(3):411-9. doi: 10.1111/j.1365-2125.1984.tb02483.x.
The effect of cimetidine (CMT; 400 mg twice daily) and matching placebo on the enzyme-inducing properties of carbamazepine (CBZ; 200 mg at night for 15 days) was studied in seven healthy male volunteers. CMT alone had no significant effect on antipyrine kinetics, urinary 6 beta-hydroxycortisol excretion or leucocyte delta-aminolaevulinic acid synthase (ALA.S) activity. CBZ increased leucocyte ALA.S activity by 204% following 1 week's treatment (P less than 0.001). Thereafter, ALA.S activity fell despite continued CBZ administration. Concomitant CMT did not influence this response. Antipyrine clearance and urinary 6 beta-hydroxycortisol excretion were both increased by CBZ after 2 weeks' treatment (P less than 0.01). CMT blocked CBZ induction of antipyrine metabolism but the rise in urinary 6 beta-hydroxycortisol excretion was unaffected. Plasma CBZ concentrations 10, 14 and 18 h following the 8th and 15th doses were higher when CMT was taken concurrently (P less than 0.05). CBZ half-life fell by 36% and clearance rose by 29% (both P less than 0.001) with placebo and by 10% and 7% (both NS) when CMT was taken concurrently. CMT inhibits CBZ auto- and hetero-induction in man. Epileptic patients receiving CBZ chronically may be at risk of toxicity if CMT is also prescribed.
在7名健康男性志愿者中研究了西咪替丁(CMT;每日两次,每次400毫克)和匹配的安慰剂对卡马西平(CBZ;每晚200毫克,共15天)酶诱导特性的影响。单独使用CMT对安替比林动力学、尿6β-羟基皮质醇排泄或白细胞δ-氨基乙酰丙酸合酶(ALA.S)活性无显著影响。CBZ治疗1周后白细胞ALA.S活性增加204%(P<0.001)。此后,尽管继续给予CBZ,ALA.S活性仍下降。同时给予CMT不影响这种反应。治疗2周后,CBZ使安替比林清除率和尿6β-羟基皮质醇排泄均增加(P<0.01)。CMT阻断了CBZ对安替比林代谢的诱导作用,但尿6β-羟基皮质醇排泄的增加未受影响。同时服用CMT时,第8剂和第15剂后10、14和18小时的血浆CBZ浓度较高(P<0.05)。服用安慰剂时,CBZ半衰期下降36%,清除率上升29%(均P<0.001),同时服用CMT时,半衰期下降10%,清除率上升7%(均无统计学意义)。CMT在人体内抑制CBZ的自身诱导和异源诱导。长期接受CBZ治疗的癫痫患者如果同时服用CMT可能有中毒风险。